Clinical trial
Amlodipine Diabetic Hypertension Efficacy Response Trial
NCT00159692 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00159692 |
|---|---|
| Title | Amlodipine Diabetic Hypertension Efficacy Response Trial |
| Official title | A Multi-Center, Randomized, Double-Blind, Double-Dummy Study Evaluating The Safety and Efficacy Of The Addition Of Amlodipine To Quinapril Or Losartan In The Treatment Of Diabetic Hypertensive Subjects |
| Acronym | ADHERE |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Amlodipine |
| Enrollment | 739 |
| Start date | Mar 1, 2003 |
| Completion | Aug 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 28, 2021 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: